RESVIQ Trademark

Trademark Overview

On Friday, October 15, 2021, a trademark application was filed for RESVIQ with the United States Patent and Trademark Office. The USPTO has given the RESVIQ trademark a serial number of 97076937. The federal status of this trademark filing is REGISTERED as of Tuesday, September 17, 2024. This trademark is owned by GlaxoSmithKline Biologicals SA. The RESVIQ trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

General Information

Serial Number97076937
Word MarkRESVIQ
Filing DateFriday, October 15, 2021
Status700 - REGISTERED
Status DateTuesday, September 17, 2024
Registration Number7504958
Registration DateTuesday, September 17, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 25, 2024

Trademark Statements

Goods and ServicesVaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, November 4, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxoSmithKline Biologicals SA
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressRixensart B-1330
BE
Party NameGlaxoSmithKline Biologicals SA
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressRixensart B-1330
BE
Party NameGlaxoSmithKline Biologicals SA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressRixensart B-1330
BE

Trademark Events

Event DateEvent Description
Tuesday, October 19, 2021NEW APPLICATION ENTERED
Thursday, November 4, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 29, 2022ASSIGNED TO EXAMINER
Friday, July 8, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 15, 2022ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Wednesday, July 20, 2022ELECTRONIC RECORD REVIEW COMPLETE
Wednesday, August 3, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 3, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 3, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 3, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, August 3, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 23, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 23, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 18, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, April 14, 2023SOU TEAS EXTENSION RECEIVED
Friday, April 14, 2023SOU EXTENSION 1 FILED
Friday, April 14, 2023SOU EXTENSION 1 GRANTED
Tuesday, April 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 20, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, September 20, 2023SOU EXTENSION 2 FILED
Wednesday, September 20, 2023SOU EXTENSION 2 GRANTED
Friday, September 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 29, 2024TEAS PETITION TO AMEND BASIS RECEIVED
Monday, April 29, 2024ASSIGNED TO PETITION STAFF
Wednesday, May 1, 2024PETITION INQUIRY LETTER ISSUED
Friday, March 29, 2024PETITION TO DIRECTOR - CHANGE BASIS - RECEIVED
Thursday, April 18, 2024SOU EXTENSION 3 FILED
Tuesday, May 7, 2024TEAS RESPONSE TO PETITION INQUIRY LETTER
Tuesday, May 7, 2024PETITION INQUIRY LETTER ISSUED
Wednesday, May 8, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Thursday, May 9, 2024PETITION GRANTED - EXTENSION REQUEST FILED
Thursday, May 9, 2024NOTICE OF REVIVAL - E-MAILED
Thursday, May 9, 2024SOU EXTENSION 3 GRANTED
Thursday, May 9, 2024ASSIGNED TO PETITION STAFF
Thursday, May 9, 2024PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Thursday, May 9, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, May 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 22, 2024NOTICE OF ALLOWANCE CANCELLED
Wednesday, May 22, 2024CASE RETURNED TO EXAMINATION
Tuesday, June 25, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 25, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, August 8, 2024ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Tuesday, September 17, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, September 17, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Wednesday, June 5, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Related Keywords

resviq treatment preparations pharmaceutical diseases disorders hepatological respiratory genitourinary cardiopulmonary neurological